Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RJ031
- Development stage
- Preclinical
- Lead developer
- Risen
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
RJ031 is a dual-target small interfering RNA (siRNA) therapeutic candidate being developed by Risen Pharma for the treatment of Alzheimer's disease. The drug utilizes RNA interference to silence the expression of two undisclosed genetic targets involved in the progression of the disease. Currently in the IND-enabling stage, RJ031 represents a novel approach to neurodegenerative disease by potentially addressing multiple pathological pathways simultaneously.
Beyond the preview
Go deeper on RJ031.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RJ031.